Abstract: Aspects described herein include devices, wireless communication apparatuses, methods, and associated operations for heatsinks integrating millimeter wave and non-millimeter wave operation. In some aspects, an apparatus comprising a millimeter wave (mmW) module is provided. The apparatus includes at least one mmW antenna and at least one mmW signal node configured to communicate a data signal in association with the at least one mmW antenna. The apparatus further includes mixing circuitry configured to convert between the data signal and a mmW signal for communications associated with the at least one mmW antenna. The apparatus further includes a heatsink comprising a non-mmW antenna and a non-mmW feed point coupled to the non-mmW antenna. The non-mmW feed point is configured to provide a signal path to the non-mmW antenna for a non-mmW signal. The heatsink is mechanically coupled to the mmW module.

Abstract: A composition and method for removing a metal-containing layer or portion of a layer of a pellicle of an EUV mask are provided. The composition includes water; one or more oxidizing agents; and one or more acids. The method includes forming one or more layers over a silicon substrate with at least one of those layers includes a metal containing layer and removing the metal containing layer by contacting the metal containing layer with the composition of the disclosed and claimed subject matter.

Abstract: A kit for detecting urothelial carcinoma is provided. The kit includes at least one primer or probe for detecting one or more miRNAs, and the one or more miRNAs are selected from the group consisting of miR-19b-1, miR-636, miR-150, miR-155, miR-183, miR-378, miR-210, miR-487, and combinations thereof. A method for detecting urothelial carcinoma is also provided. The method includes detecting the expression level(s) of one or more miRNAs in a sample of a subject, and the one or more miRNAs are selected from the group consisting of miR-19b-1, miR-636, miR-150, miR-155, miR-183, miR-378, miR-210, miR-487, and combinations thereof.

Abstract: A method for estimating a risk for a subject suffering from an urothelial carcinoma is provided, including measuring an expression level of at least one miRNA in a sample of the subject, and the miRNA is selected from miR-1274, miR-19a, miR-30, and miR-708; and comparing the expression level of the same miRNA in the sample to that of a control for estimating whether the subject has the risk of suffering from the urothelial carcinoma or not. A kit for estimating a risk for a subject suffering from an urothelial carcinoma is also provided, including at least one reagent for detecting an expression level of at least one miRNA as above mentioned in a sample of the subject.

Abstract: A kit for detecting urothelial carcinoma is provided. The kit includes at least one primer or probe for detecting one or more miRNAs, and the one or more miRNAs are selected from the group consisting of miR-19b-1, miR-636, miR-150, miR-155, miR-183, miR-378, miR-210, miR-487, and combinations thereof. A method for detecting urothelial carcinoma is also provided. The method includes detecting the expression level(s) of one or more miRNAs in a sample of a subject, and the one or more miRNAs are selected from the group consisting of miR-19b-1, miR-636, miR-150, miR-155, miR-183, miR-378, miR-210, miR-487, and combinations thereof.

Abstract: A medical magnetic pellet is provided. The magnetic pellet includes a porous matrix and magnetic powder distributed in the porous matrix. Moreover, an active substance also can be added to be distributed in the matrix. The porous matrix of the magnetic pellet can carry active substances or absorb target substances.

Abstract: A vegetarian pore-sealing capsule is provided. The pore-sealing capsule may release active substances in a gastrointestinal tract, including stomach, duodenum, jejunum, ileum and colon, under control. The pore-sealing capsule includes a capsule shell having one or more pores and a pore-sealing material for sealing at least one of the pores. When the pore-sealing capsule is located at a destination inside the gastrointestinal tract, the pore-sealing material will leave the pores.

Abstract: Disclosed herein is an active pellet. The active pellet includes a body and interspaces. The body includes an active ingredient ranging from 50 to 100 wt %, free of chemical additives.

Abstract: Disclosed herein is an active pellet. The active pellet includes a body and interspaces. The body includes an active ingredient ranging from 50 to 100 wt %, free of chemical additives.